PURPOSE: Chemotherapy-induced alopecia is very distressing for a patient and may have an impact on treatment decisions. On docetaxel-based therapy, alopecia occurs in a substantial proportion of patients. We aimed to investigate whether two different methods of scalp cooling can prevent hair loss. METHODS: In this open-label, prospective, nonrandomized trial, patients with solid tumors receiving docetaxel in a palliative setting were allocated according to patients' preference to short-term cooling (over 45 min postinfusion) with a Paxman PSC-2 machine (PAX), with cold cap (CC), or no cooling. The combined endpoint was alopecia World Health Organisation (WHO) III or IV or the necessity to wear a wig. Study identifier is Clinicaltrials.gov NCT01008774. RESULTS: Two hundred thirty-eight patients were included in the trial (128 patients PAX, 71 CC, and 39 no cooling). Number of cycles (median 4) and median docetaxel doses were similar across groups (55-60 mg/day on weekly therapy, 135-140 mg/day on 3-weekly therapy). Alopecia occurred with PAX, CC, and no cooling under 3-weekly docetaxel in 23, 27, and 74% and under weekly docetaxel in 7, 8, and 17%, respectively. Overall, cooling (PAX and CC combined) reduced risk of alopecia by 78% (hazard ratio 0.22; 95% confidence interval 0.12 to 0.41). CC and PAX prophylaxis led to the same degree of prevention of alopecia. Adverse events (AE) were reported in 5% (most frequently, sensation of cold), and 30 patients (13%) discontinued cooling measures after cycle 1. CONCLUSIONS: In this first comparison published to date, both PAX and CC offer efficacious protection against hair loss, in particular when docetaxel is administered in a 3-weekly interval.
PURPOSE: Chemotherapy-induced alopecia is very distressing for a patient and may have an impact on treatment decisions. On docetaxel-based therapy, alopecia occurs in a substantial proportion of patients. We aimed to investigate whether two different methods of scalp cooling can prevent hair loss. METHODS: In this open-label, prospective, nonrandomized trial, patients with solid tumors receiving docetaxel in a palliative setting were allocated according to patients' preference to short-term cooling (over 45 min postinfusion) with a Paxman PSC-2 machine (PAX), with cold cap (CC), or no cooling. The combined endpoint was alopecia World Health Organisation (WHO) III or IV or the necessity to wear a wig. Study identifier is Clinicaltrials.gov NCT01008774. RESULTS: Two hundred thirty-eight patients were included in the trial (128 patientsPAX, 71 CC, and 39 no cooling). Number of cycles (median 4) and median docetaxel doses were similar across groups (55-60 mg/day on weekly therapy, 135-140 mg/day on 3-weekly therapy). Alopecia occurred with PAX, CC, and no cooling under 3-weekly docetaxel in 23, 27, and 74% and under weekly docetaxel in 7, 8, and 17%, respectively. Overall, cooling (PAX and CC combined) reduced risk of alopecia by 78% (hazard ratio 0.22; 95% confidence interval 0.12 to 0.41). CC and PAX prophylaxis led to the same degree of prevention of alopecia. Adverse events (AE) were reported in 5% (most frequently, sensation of cold), and 30 patients (13%) discontinued cooling measures after cycle 1. CONCLUSIONS: In this first comparison published to date, both PAX and CC offer efficacious protection against hair loss, in particular when docetaxel is administered in a 3-weekly interval.
Authors: S T Davis; B G Benson; H N Bramson; D E Chapman; S H Dickerson; K M Dold; D J Eberwein; M Edelstein; S V Frye; R T Gampe; R J Griffin; P A Harris; A M Hassell; W D Holmes; R N Hunter; V B Knick; K Lackey; B Lovejoy; M J Luzzio; D Murray; P Parker; W J Rocque; L Shewchuk; J M Veal; D H Walker; L F Kuyper Journal: Science Date: 2001-01-05 Impact factor: 47.728
Authors: Hope S Rugo; Paula Klein; Susan Anitra Melin; Sara A Hurvitz; Michelle E Melisko; Anne Moore; Glen Park; Jules Mitchel; Erika Bågeman; Ralph B D'Agostino; Elizabeth S Ver Hoeve; Laura Esserman; Tessa Cigler Journal: JAMA Date: 2017-02-14 Impact factor: 56.272
Authors: Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture Journal: Eur J Dermatol Date: 2016-10-01 Impact factor: 3.328
Authors: Joanne M Shaw; Jane O'Brien; Susan Chua; Richard De Boer; Rachel Dear; Nicholas Murray; Fran Boyle Journal: Support Care Cancer Date: 2017-08-29 Impact factor: 3.603
Authors: Manon M C Komen; Wim P M Breed; Carolien H Smorenburg; Tjeerd van der Ploeg; S H Goey; Jacobus J M van der Hoeven; Johan W R Nortier; Corina J G van den Hurk Journal: Support Care Cancer Date: 2016-01-25 Impact factor: 3.603
Authors: V V Shah; T C Wikramanayake; G M DelCanto; C van den Hurk; S Wu; M E Lacouture; J J Jimenez Journal: J Eur Acad Dermatol Venereol Date: 2017-11-24 Impact factor: 6.166
Authors: Kathryn J Ruddy; Jennifer Le-Rademacher; Mario E Lacouture; Mary Wilkinson; Adedayo A Onitilo; Amy C Vander Woude; Maria T Grosse-Perdekamp; Travis Dockter; Angelina D Tan; Andreas Beutler; Charles L Loprinzi Journal: Breast Date: 2019-09-19 Impact factor: 4.380